Multiple Myeloma | What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma

Featuring an interview with Prof Philippe Moreau, including the following topics: Perspectives on efficacy outcomes with and toxicity profiles of daratumumab and isatuximab (0:00) Selection of an anti-CD38 antibody for initial treatment of multiple myeloma (MM) (7:28) Approach to maintenance therapy for transplant-eligible patients with MM (15:47) Management of MM in older patients; treatment approaches for t(11;14) MM (22:47) Management of relapsed/refractory MM (29:49) Management of anti-CD38 antibody-associated side effects (35:45) Other relevant clinical scenarios in MM — Plasma cell leukemia, smoldering myeloma (41:19) Perspectives on the future landscape of up-front treatment for MM (45:02) CME information and select publications